Fairmount Funds Management LLC Keros Therapeutics, Inc. Transaction History

Fairmount Funds Management LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$26.03 - $67.04 $3.24 Million - $8.34 Million	-124,413 Reduced 31.35%	272,498 $7.53 Million
Q1 2022 May 16, 2022	BUY	$42.12 - $59.36 $4.38 Million - $6.18 Million	104,078 Added 35.54%	396,911 $21.6 Million
Q4 2021 Feb 14, 2022	BUY	$36.95 - $62.89 $5.3 Million - $9.02 Million	143,500 Added 96.09%	292,833 $17.1 Million
Q2 2021 Aug 13, 2021	BUY	$42.4 - $70.11 $1.7 Million - $2.8 Million	40,000 Added 36.59%	149,333 $6.34 Million
Q1 2021 May 14, 2021	BUY	$54.0 - $75.28 $5.9 Million - $8.23 Million	109,333 New	109,333 $6.73 Million

157

27.1M

28.7K

1.8K

Ticker KROS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,757,000
Market Cap $1.45B
Description
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed ...

Get notified when there are updates to the investment portfolio of Fairmount Funds Management LLC, based on Form 13F filings with the SEC.

Stay updated on Fairmount Funds Management LLC with notifications on news.